0
Adial Pharmaceuticals, Inc Banner Image

Adial Pharmaceuticals, Inc has reached its limit for free report views

Work for Adial Pharmaceuticals, Inc? Upgrade Your Profile and unlock all your annual reports.

Adial Pharmaceuticals, Inc

  • Ticker ADIL
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Adial Pharmaceuticals, Inc Logo Image
  • 1-10 Employees
  • Based in Charlottesville, Virginia
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (“AUD”). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinkingMore, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.
Adial Pharmaceuticals, Inc

Most Recent Annual Report

Adial Pharmaceuticals, Inc MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Adial Pharmaceuticals, Inc has reached its limit for free report views.

Older/Archived Annual Reports